Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: Results from the randomized CLL17 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

VLVesa LindströmCNCarsten Utoft NiemannTTTamar Tadmor

Discussion

Loading...

Member takes

Overview

Randomized phase 3 trial compares fixed-duration venetoclax and obinutuzumab to continuous ibrutinib, indicating non-inferiority for CLL treatment.

Key Points

  • Three-year progression-free survival was similar in fixed-duration venetoclax plus obinutuzumab and continuous ibrutinib treatments.
  • Both treatment arms showed high overall response rates, with 84.2% for venetoclax and obinutuzumab and 88.5% for venetoclax plus ibrutinib.
  • Analysis from the randomized phase 3 trial compared treatment effectiveness for chronic lymphocytic leukemia.
  • Fixed-duration therapies may offer viable alternatives to continuous treatment with ibrutinib for previously untreated CLL patients.

Cite This Study

Lindström et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e180https://doi.org/10.1182/blood-2025-1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Upfront continuous BTK inhibitor (BTKi) versus time-limited venetoclax-BTKi combinations in CLL across IGHV subgroups: Results of an indirect analysis2025
  2. 2Real-world comparison of BTKi monotherapy and fixed-duration BTKi–Venetoclax for first line treatment of chronic lymphocytic leukemia patients without TP53 mutations or IGHV rearrangement2025
  3. 3Outcomes with a fixed duration combination of bruton tyrosine kinase inhibitors and venetoclax in chronic lymphocytic leukemia: A systematic review and meta-analysis2025
  4. 4Real‑world effectiveness and patient-centered outcomes of fixed‑duration vs continuous first‑line therapy in chronic lymphocytic leukemia (CLL)2025
  5. 5Efficacy of fixed-duration venetoclax-based regimens as first-line in chronic lymphocytic leukemia: A systematic review and meta-analysis of clinical trials2025